{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:04:37Z","timestamp":1780409077737,"version":"3.54.1"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"PRIN 2015","award":["2015ZHKFTA"],"award-info":[{"award-number":["2015ZHKFTA"]}]},{"DOI":"10.13039\/501100003407","name":"Ministry of Education, University and\n                    Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background Acromegaly is associated with an increased risk of fatal and\n                    non-fatal cardiovascular (CV) events. Controlling acromegaly decreases, but does\n                    not normalize this risk. Brain natriuretic peptide (BNP) assessment is used in\n                    the general population for the diagnosis of heart failure and to predict\n                    ischemic recurrences and mortality. This is a retrospective, longitudinal,\n                    monocenter study that evaluates the role of serum N-terminal fragment of BNP\n                    (NT-pro-BNP) for predicting CV events in acromegaly patients.<\/jats:p><jats:p>\n          Methods Serum NT-pro-BNP levels were measured in 76 patients with\n                    acromegaly (23 males, 57.7\u00b11.5 years), and compared with other\n                    predictors of CV events. NT-pro-BNP cut-off value discriminating the occurrence\n                    of CV events was determined by ROC analysis. CV events were recorded during a\n                    follow-up of 78.6\u00b16.4 months.<\/jats:p><jats:p>\n          Results CV events occurred in 9.2% of patients. Mean\n                    log(NT-pro-BNP) concentration was higher in patients who experienced CV events\n                    than in those who did not (p&lt;0.01) and in patients who died due to CV\n                    events than in those who died due to other causes (p&lt;0.01). Based on the\n                    ROC curve, a cut-off value of 91.55\u2009pg\/mL could predict CV\n                    events (OR 19.06). Log(NT-pro-BNP) was lower in surgically treated patients by\n                    surgery (p&lt;0.05), and in those cured by neurosurgery\n                    (p&lt;0.02).<\/jats:p><jats:p>\n          Conclusions High NT-pro-BNP value is an independent middle-term predictor\n                    of fatal or non-fatal CV events in patients with acromegaly. According to this\n                    parameter, surgically treated patients show lower CV risk than those managed\n                    with medical therapy, especially if the disease is cured.<\/jats:p>","DOI":"10.1055\/a-1540-5009","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T23:45:23Z","timestamp":1640303123000},"page":"229-236","source":"Crossref","is-referenced-by-count":6,"title":["Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly\n                    Patients"],"prefix":"10.1055","volume":"130","author":[{"given":"Marta","family":"Ragonese","sequence":"additional","affiliation":[{"name":"Department of Human Pathology DETEV, University of Messina, Messina,\n                    Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Di Bella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of\n                    Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, University of Messina, Messina,\n                    Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Grasso","sequence":"additional","affiliation":[{"name":"Service of Immunometry and Laboratory Diagnosis, University Hospital\n                    \u201cG. Martino\u201d, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Alibrandi","sequence":"additional","affiliation":[{"name":"Department of Economics, University of Messina, Messina,\n                    Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiseppe","family":"Giuffrida","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of\n                    Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacarla","family":"Moleti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of\n                    Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferra\u00f9","sequence":"additional","affiliation":[{"name":"Department of Human Pathology DETEV, University of Messina, Messina,\n                    Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[{"name":"Department of Human Pathology DETEV, University of Messina, Messina,\n                    Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref2","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"S Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and\n                    meta-analysis","volume":"179","author":"F Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11154-019-09506-y","article-title":"Current perspectives on the impact of clinical disease and biochemical control\n                    on comorbidities and quality of life in acromegaly","volume":"20","author":"F Gatto","year":"2019","journal-title":"Rev Endocr Metab Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1210\/jc.2005-2857","article-title":"Acromegaly and coronary disease: an integrated evaluation of conventional\n                    coronary risk factors and coronary calcifications detected by computed\n                    tomography","volume":"91","author":"S Cannav\u00f2","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","first-page":"206","article-title":"Cardiovascular events in acromegaly: distinct role of Agatston and Framingham\n                    score in the 5-year prediction","volume":"47","author":"M Ragonese","year":"2014","journal-title":"Endocrine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart","volume":"54","author":"A Colao","year":"2001","journal-title":"Clin Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2265.2007.03047.x","article-title":"High prevalence of cardiac hypertophy without detectable signs of fibrosis in\n                    patients with untreated active acromegaly: an in vivo study using magnetic\n                    resonance imaging","volume":"68","author":"F Bogazzi","year":"2008","journal-title":"Clin Endocrinol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","article-title":"Quantification of coronary artery calcium using ultrafast computed\n                    tomography","volume":"15","author":"A S Agatston","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10554-014-0519-4","article-title":"Automatic detection and quantification of the agatston coronary artery calcium\n                    score on contrast computed tomography angiography","volume":"31","author":"W Ahmed","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham\n                    Heart Study","volume":"117","author":"RBSr D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00392-005-0205-6","article-title":"N-terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction. A study in\n                    patients with suspected cardiac disorders","volume":"94","author":"G Hess","year":"2005","journal-title":"ZS Kardiologie"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejheart.2003.10.003","article-title":"N-terminal pro-brain natriuretic peptide for discriminating between cardiac and\n                    non-cardiac dyspnoea","volume":"6","author":"L S Nielsen","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of\n                    heart failure","volume":"347","author":"A S Maisel","year":"2002","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199009133231114","article-title":"Increased human brain natriuretic peptide in congestive heart failure","volume":"323","author":"M Mukoyama","year":"1990","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa011053","article-title":"The prognostic value of B- type natriuretic peptide in patients with acute\n                    coronary syndromes","volume":"345","author":"J A de Lemos","year":"2001","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0735-1097(03)00168-2","article-title":"Evaluation of B-type natriuretic peptide for risk assessment in Unstable\n                    Angina\/Non\u2013ST elevation myocardial infarction: B-type\n                    natriuretic peptide and prognosis in TAC TICS-TIMI 18","volume":"41","author":"D A Morrow","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/BF03346650","article-title":"N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly","volume":"33","author":"S Arikan","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11102-010-0240-9","article-title":"Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic\n                    resonance imaging and B-type natriuretic peptides","volume":"13","author":"M Andreassen","year":"2010","journal-title":"Pituitary"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/EJE-19-0470","article-title":"Relation of IGF-1 with subclinical cardiovascular markers including intima-media\n                    thickness, left ventricular mass index and NT-proBNP","volume":"182","author":"M Eichner","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"S Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","article-title":"A consensus on the diagnosis and treatment of acromegaly complications","volume":"16","author":"S Melmed","year":"2013","journal-title":"Pituitary"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/cen.13273","article-title":"Cystatin-C and epicardial adipose tissue as noninvasive predictors of\n                    cardiovascular risk in acromegaly","volume":"86","author":"A Aulinas","year":"2017","journal-title":"Clin Endocrinol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1440-1681.2008.04894.x","article-title":"Can measurement of B-type natriuretic peptide levels improve cardiovascular\n                    disease prevention?","volume":"35","author":"D J Campbell","year":"2008","journal-title":"Clin Exp Pharmacol P"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11102-007-0067-1","article-title":"Serum markers of cardiovascular risk in patients with acromegaly before and\n                    after six months of treatment with octreotide LAR","volume":"11","author":"B J Potter","year":"2008","journal-title":"Pituitary"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/EJE-12-0753","article-title":"Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum\n                    levels: insights from the Belgian registry of acromegaly","volume":"168","author":"J Verhelst","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1253\/circj.71.1955","article-title":"Relationship between insulin-like growth factor-I and brain natriuretic peptide\n                    in patients with acromegaly after surgery","volume":"71","author":"M Ito","year":"2007","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2265.2007.02782.x","article-title":"N-terminal pro-B-type natriuretic peptide in patients with growth hormone\n                    disturbances","volume":"66","author":"M Andreassen","year":"2007","journal-title":"Clin Endocrinol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-2006-954588","article-title":"Effects of growth hormone treatment on B-type natriuretic peptide as a marker of\n                    heart failure in adults with growth hormone deficiency","volume":"38","author":"H Wallaschofski","year":"2006","journal-title":"Horm Metab Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/00365513.2012.685887","article-title":"Impact of growth hormone (GH) treatment on circulating NT-proBNP concentrations\n                    and on cardiac function in adult GH deficient patients","volume":"72","author":"D Gruson","year":"2012","journal-title":"Scand J Clin Lab Inv"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0033-1336743","article-title":"Cardiac risk in patients with treatment na\u00efve, first-line medically\n                    controlled and first-line surgically cured acromegaly in comparison to matched\n                    data from the general population","volume":"121","author":"C Berg","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and\n                    successful surgery in acromegaly: effects on cardiovascular risk factors","volume":"91","author":"C L Ronchi","year":"2006","journal-title":"J Clin Endocr Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on\n                    cardiomyopathy","volume":"93","author":"A Colao","year":"2008","journal-title":"J Clin Endocr Metab"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1540-5009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:48:10Z","timestamp":1651798090000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1540-5009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":32,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,4,27]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1540-5009","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}